Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Codiak

Codiak
2015 FOUNDED
PRIVATE STATUS
81-90 EMPLOYEES
IPO LATEST DEAL TYPE (Cancelled)
$86.2M LATEST DEAL AMOUNT
10 INVESTORS
Description

Developer of novel therapeutics intended to pioneer a new class of biologic medicines. The company's therapeutics harnesses exosomes-natural intercellular messengers to deliver potent signals to specific cell targets by using biologically active molecules, nucleic acids, antibodies, enzymes, cytokines and complex ligands, enabling medical practitioners to treat oncology, immune-based, metabolic and fibrotic diseases effectively.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 500 Technology Square
  • 9th Floor
  • Cambridge, MA 02139
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Codiak’s full profile, request a free trial.

Codiak Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. IPO 01-Jul-2019 $86.2M Cancelled Pre-Clinical Trials
3. Later Stage VC (Series C) 29-Nov-2017 000.00 00000 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 26-Jan-2016 $61M $92M 00000 Completed Product Development
1. Early Stage VC (Series A) 25-Nov-2015 $31M $31M 0000 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Codiak Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 00.00
Series B 00,000,000 00.000000 00.00 00 00 00 00 00.000
Series A 33,200,000 $0.000100 $0.08 $1 $1 1x $1 31.4%
To view this company’s complete Cap Table, request access »

Codiak Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evox Therapeutics Venture Capital-Backed Oxford, United Kingdom 0 000.00 0000000000 000.00
000000 00000000 Venture Capital-Backed Buffalo, NY 00.000 0000000000 0 00.000
0000000 000000 Formerly VC-backed Redwood City, CA 000 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed Menlo Park, CA 00 00000 00000000000 00000
00000000 Formerly VC-backed San Diego, CA 0000 00000 000000&0
To view this company’s complete list of competitors, request access »

Codiak Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Casdin Capital Hedge Fund Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
Qatar Investment Authority Sovereign Wealth Fund Minority 000 0000 000000 0
Sirona Biochem PE-Backed Company Minority 000 0000 000000 0
Tavistock Group PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Codiak Executive Team (13)

Name Title Board
Seat
Contact
Info
Douglas Williams Ph.D President, Chief Executive Officer & Board Member
Linda Bain Chief Financial Officer
Andrea DiFabio JD Chief Legal Officer
Richard Brudnick Chief Business Officer & Head, Strategy
Robert Brenner MD Executive Vice President, Research & Development

3 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

Codiak Board Members (9)

Name Representing Role Since Contact
Info
Avak Kahvejian Ph.D Flagship Pioneering Board Member 000 0000
Briggs Morrison MD Self Board Member 000 0000
Charles Cooney Ph.D Self Board Member 000 0000
Eric Lander Ph.D Self Scientific Co-Founder & Board Member 000 0000
Jonathan Poole Self Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »